BRCA1 and neoplasm: Patients harboring pathogenic/likely pathogenic tumor BRCA1/2 mutations may be eligible for PARPi therapy, according to clinical characteristics, and directed to genetic counseling, during which a peripheral blood sample will be tested to evaluate the germline nature of the alteration identified.